D.A. Davidson & Co. Adaptimmune Therapeutics PLC Transaction History

D.A. Davidson & Co.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 13, 2019	SELL	$3.63 - $6.06 $40,652 - $67,865	-11,199 Closed	0 $0
Q4 2018 Jan 29, 2019	SELL	$3.76 - $14.16 $47,658 - $179,478	-12,675 Reduced 53.09%	11,199 $64,000
Q3 2018 Nov 13, 2018	SELL	$8.27 - $13.56 $210,339 - $344,885	-25,434 Reduced 51.58%	23,874 $324,000
Q2 2018 Aug 02, 2018	SELL	$10.42 - $13.74 $14,035 - $18,507	-1,347 Reduced 2.66%	49,308 $585,000
Q1 2018 May 04, 2018	SELL	$7.1 - $11.56 $10,131 - $16,496	-1,427 Reduced 2.74%	50,655 $569,000
Q4 2017 Feb 08, 2018	SELL	$6.68 - $8.74 $16,225 - $21,229	-2,429 Reduced 4.46%	52,082 $348,000
Q3 2017 Nov 08, 2017	BUY	$4.93 - $8.93 $91,205 - $165,205	18,500 Added 51.37%	54,511 $446,000
Q2 2017 Aug 11, 2017	BUY	N/A	36,011	36,011 $0

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $98M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

Stay updated on D.A. Davidson & Co. with notifications on news.